Parkinson's Disease, Balsamo (Zambon): "Innovation for Quality of Life"

Il Tempo

Lean Right

Factuality

Ownership

Rome, 2 Sep. (Adnkronos Salute) - • The Ema approval of the new modified-release levodopa carbidopa combination (Hopledo*) for the treatment of motor fluctuations in Parkinson's disease represents a further step in Zambon's multi-year commitment to neurosciences and above all aims to respond to the needs still unanswered on the management of motor fluctuations that are estimated to affect about 80% of patients with Parkinson's disease within 10…

Quotidiano Nazionale

Factuality

Ownership

"80% people with Parkinson's have motor fluctuations within 10 years of diagnosis. This therapy responds to the need to manage them by patients."

Forbes España

Factuality

Ownership

The ageing of the European population is forcing health systems to cope not only with a higher prevalence of neurodegenerative diseases, but also with their growing economic and social bill. Parkinson’s disease is a good example. Its prevalence in Europe has practically doubled since 1990 and the associated cost [...] La entrada Parkinson’s disease costs Europe almost 30 million euros a year aparece primero en Forbes España.

www.prensa-latina.cu

Factuality

Ownership

Geneva, Sep 1 (Latin Press) The European Academy of Neurology reported today that the annual social cost of Parkinson's disease in Europe reached €22.8 billion in 2019, equivalent to €28.8 billion at 2025 prices. The post Parkinson's disease brings millions of losses in Europe first appeared on News Prensa Latina.

Deutsches Ärzteblatt

Factuality

Ownership

Duisburg/Essen – Parkinson's disease causes enormous social costs in Europe: in 2019 alone, it amounted to 22.8 billion euros. In addition, the price level of 2025 corresponds to a current study published in Movement Disorders, according to 28.8 billion euros (2026; DOI: 10,1002/mds.70491). In view of the...